Used in the treatment of severe inflammatory conditions, particularly in cases of complement-mediated disorders. It targets the complement protein C5, inhibiting its activation and preventing the formation of the membrane attack complex (MAC), which is responsible for cell lysis and tissue damage. This makes it valuable in diseases where uncontrolled complement activation plays a key role, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Investigated for use in autoimmune diseases and transplant rejection due to its ability to modulate immune-mediated damage. Also studied in acute respiratory distress syndrome (ARDS), including in severe COVID-19 patients, to reduce lung inflammation and improve oxygenation by controlling excessive complement activation in the lungs.